1-benzyl-4-(2-chloro-phenyl)-4-methyl-piperidine | 849106-49-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-benzyl-4-(2-chloro-phenyl)-4-methyl-piperidine
• 英文别名: 1-benzyl-4-(2-chloro-phenyl)-4-methylpiperidine；1-Benzyl-4-(2-chlorophenyl)-4-methylpiperidine
• CAS: 849106-49-6
• 化学式: C₁₉H₂₂ClN
• 分子量: 299.843
• InChiKey: LICNPGVMUVZEPG-UHFFFAOYSA-N

物化性质

• 沸点：
  395.5±42.0 °C(Predicted)
• 密度：
  1.108±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-benzyl-4-(2-chloro-phenyl)-4-methyl-piperidine 在 1-氯乙基氯甲酸酯 、 potassium iodide 作用下， 以 甲醇 、 1,2-二氯乙烷 、 异丙醇 为溶剂， 反应 24.0h， 生成 2-(5-{3-[4-(2-chloro-phenyl)-4-methyl-piperidin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol
  参考文献：
  名称：

  CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

  摘要：

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。

  公开号：

  US20160031908A1
• 作为产物：
  描述：

  N-苄基哌啶酮 在 aluminum (III) chloride 、 甲基锂 作用下， 以 四氢呋喃 为溶剂， 反应 5.0h， 生成 1-benzyl-4-(2-chloro-phenyl)-4-methyl-piperidine
  参考文献：
  名称：

  CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF

  摘要：

  揭示了新颖的化合物以及治疗与异常白细胞召集和/或激活相关的疾病的方法。该方法包括向需要的受试者施用代表的化合物的有效量： 或其生理上可接受的盐。

  公开号：

  US20160031908A1

文献信息

• Chemokine receptor antagonists and methods of use thereof
  申请人：Luly R. Jay

  公开号：US20050070549A1

  公开（公告）日：2005-03-31

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: formula (1) or physiologically acceptable salt thereof.

  揭示了新化合物和一种治疗与异常白细胞召集和/或激活相关疾病的方法。该方法包括向需要的受试者施用由以下公式（1）表示的化合物或其生理上可接受的盐的有效量。
• [EN] (4-PHENYL-PIPERIDIN-1-YL)-[5-1H-PYRAZOL-4YL)-THIOPHEN-3-YL]-METHANONE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS DE (4-PHÉNYL-PIPÉRIDIN-1-YL)-[5-1H-PYRAZOL-4-YL)-THIOPHÉN-3-YL]-MÉTHANONE ET LEUR UTILISATION
  申请人：UNIV EDINBURGH

  公开号：WO2011033255A1

  公开（公告）日：2011-03-24

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)- [5-(1 H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 1 1 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明一般涉及治疗化合物领域。更具体地说，本发明涉及某些（4-苯基-哌啶-1-基）-[5-(1 H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，其中包括抑制11β-羟基甾酮脱氢酶1（11β-HSD1）的作用。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体外和体内抑制11β-羟基甾酮脱氢酶1的用途；治疗通过抑制11β-羟基甾酮脱氢酶1而得到改善的疾病；治疗代谢综合征，其中包括2型糖尿病和肥胖等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质紊乱和缺血性（冠状动脉）心脏病等心血管疾病；治疗轻度认知障碍和早期痴呆等中枢神经系统疾病，包括阿尔茨海默病等。
• CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR
  申请人：Luly Jay R.

  公开号：US20090281081A1

  公开（公告）日：2009-11-12

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  本发明涉及新化合物以及一种治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受体内给予一种有效量的化合物，该化合物表示为：或其生理上可接受的盐。
• Chemokine receptor antagonists and methods of use therefor
  申请人：Luly R. Jay

  公开号：US20070060592A1

  公开（公告）日：2007-03-15

  Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an effective amount of a compound represented by: or physiologically acceptable salt thereof.

  本发明涉及一种新型化合物和一种治疗与异常白细胞招募和/或激活相关的疾病的方法。该方法包括向需要治疗的受体内投与有效量的化合物，所述化合物的表示式为：或其生理上可接受的盐。
• (4-Phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone Compounds and Their Use
  申请人：Webster Scott Peter

  公开号：US20120172393A1

  公开（公告）日：2012-07-05

  The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

  本发明涉及治疗化合物领域。更具体地说，本发明涉及某些(4-苯基哌啶-1-基)-[5-(1H-吡唑-4-基)-噻吩-3-基]-甲酮化合物，其中包括抑制11β-羟化类固醇脱氢酶1型(11β-HSD1)的化合物。本发明还涉及包含此类化合物的制药组合物的使用，以及在体外和体内使用此类化合物和组合物以抑制11β-羟化类固醇脱氢酶1型；治疗由抑制11β-羟化类固醇脱氢酶1型改善的疾病；治疗代谢综合征，包括2型糖尿病和肥胖症等疾病，以及相关疾病，包括胰岛素抵抗、高血压、脂质代谢异常和心血管疾病，如缺血性(冠状)心脏病；治疗轻度认知障碍和早期痴呆等中枢神经系统疾病，包括阿尔茨海默病等。